Could GLP-1 Medications Help Prevent Alzheimer’s Disease? What the New Research Means for Brain Health, ADHD, and Integrative Psychiatry
- Ryan Sheridan, NP
- 1 hour ago
- 6 min read
By Ryan Sheridan, DNP, PMHNP-BC | Proactive Psychiatry
TL;DR
A new 2026 systematic review suggests that GLP-1 receptor agonists (GLP-1 medications such as semaglutide, Wegovy®, Ozempic®, liraglutide, and others) may have significant neuroprotective effects that extend far beyond weight loss and diabetes treatment.
In animal models, these medications consistently reduced two of Alzheimer’s disease’s hallmark pathologies: amyloid-beta plaques and tau tangles. Human studies remain limited, but early evidence suggests GLP-1 medications may improve brain metabolism, reduce inflammation, and potentially lower future dementia risk.
While we are not yet at the point where GLP-1 medications can be recommended specifically to prevent Alzheimer’s disease, the research highlights something I discuss frequently with patients: brain health is metabolic health.
This concept is especially relevant in integrative psychiatry and ADHD treatment, where insulin resistance, inflammation, poor sleep, obesity, sedentary behavior, and cardiometabolic dysfunction can significantly impact cognitive performance decades before dementia ever develops.
The Emerging Connection Between Metabolic Health and Brain Health
For decades, Alzheimer’s disease was viewed primarily as a disease of aging and genetics.
Today, a growing body of research suggests something much more complex.
Many researchers now describe Alzheimer’s disease as involving profound metabolic dysfunction within the brain itself. Some have even referred to Alzheimer’s as “Type 3 Diabetes” due to the strong association between impaired insulin signaling and neurodegeneration.
This perspective has major implications.
If metabolic dysfunction contributes to Alzheimer’s disease, then treatments that improve metabolic health may help protect the brain long before symptoms appear.
That is where GLP-1 receptor agonists enter the conversation.
What Are GLP-1 Receptor Agonists?
GLP-1 receptor agonists are medications originally developed for type 2 diabetes.
Examples include:
Semaglutide (Ozempic, Wegovy)
Liraglutide
Tirzepatide (Zepbound)
Retatrutide
Most people know these medications because of their remarkable effects on weight loss.
However, GLP-1 receptors are not limited to the pancreas.
They are found throughout the brain, including areas involved in:
Memory
Learning
Executive function
Appetite regulation
Reward processing
Neuroinflammation
Researchers are increasingly interested in whether these medications may directly affect brain aging and neurodegenerative disease.
The New 2026 Systematic Review
A recently published systematic review in Molecular and Cellular Neuroscience examined the effects of GLP-1 receptor agonists on Alzheimer’s disease pathology.
Researchers reviewed both preclinical and human studies involving:
Semaglutide
Liraglutide
Dulaglutide
Exenatide
The review focused on the two major pathological hallmarks of Alzheimer’s disease:
1. Amyloid-Beta (Aβ)
Amyloid-beta proteins can accumulate into plaques that interfere with neuronal communication and contribute to neurodegeneration.
2. Hyperphosphorylated Tau
Tau proteins normally help stabilize neuronal structures.
When tau becomes abnormally phosphorylated, it can form neurofibrillary tangles that impair neuronal function and accelerate cognitive decline.
The Preclinical Evidence Was Remarkably Consistent
The strongest findings came from animal and cellular studies.
Among 30 preclinical studies:
Amyloid Reduction
22 out of 30 studies demonstrated reductions in amyloid-beta pathology.
Tau Reduction
19 out of 30 studies demonstrated reductions in tau hyperphosphorylation and tau-related pathology.
The review authors concluded:
“Collectively, these results point overwhelmingly to the view that administration of GLP-1RAs in preclinical models of Alzheimer’s disease lead to significant reductions in the pathophysiological hallmarks of Alzheimer’s disease.”
That is an unusually strong statement for a systematic review.
Liraglutide showed the most consistent evidence because it has been studied longest.
Dulaglutide also demonstrated particularly promising effects on both pathology and cognition in animal models.
Semaglutide’s results were largely positive, although data remain more limited.
Why Haven’t Human Studies Shown the Same Dramatic Results?
This is where the conversation becomes more nuanced.
Two human clinical trials included in the review produced relatively modest findings.
One exenatide trial showed reductions in plasma amyloid biomarkers but no meaningful cognitive improvement.
A liraglutide study failed to demonstrate significant cognitive benefits but did preserve cerebral glucose metabolism.
That may sound disappointing.
I view it differently.
The problem may not be the drug.
The problem may be timing.
Prevention Is Different Than Treatment
Imagine pushing a boulder downhill.
Stopping it at the top is relatively easy.
Stopping it halfway down the mountain is much harder.
Stopping it once it has reached full speed may be nearly impossible.
Alzheimer’s disease likely behaves similarly.
Research suggests amyloid accumulation begins 15 to 25 years before symptoms appear.
By the time memory problems emerge, substantial neurological damage may already exist.
Most Alzheimer’s clinical trials enroll patients after cognitive decline has already begun.
This raises an important question:
What if interventions need to start decades earlier?
This is one reason why prevention-focused metabolic psychiatry has become increasingly important.
Waiting until disease appears may be waiting too long.
Four Potential Mechanisms Through Which GLP-1 Medications May Protect the Brain
1. Improved Brain Insulin Signaling
The brain is highly dependent on insulin signaling.
When insulin resistance develops, neurons become less efficient at utilizing glucose.
This phenomenon is commonly observed in Alzheimer’s disease.
GLP-1 receptor agonists may improve neuronal insulin sensitivity and restore metabolic health.
For psychiatrists, this is especially interesting because insulin resistance is also associated with:
Depression
ADHD
Cognitive dysfunction
Brain fog
Executive dysfunction
2. Reduced Neuroinflammation
Chronic inflammation appears to be a major driver of neurodegeneration.
Activated microglia can release inflammatory cytokines such as:
IL-1β
TNF-α
IL-6
These inflammatory molecules can damage neurons and accelerate cognitive decline.
GLP-1 medications appear to reduce this inflammatory signaling.
This anti-inflammatory effect may help explain some of the cognitive and mood improvements reported by certain patients.
3. Improved Amyloid Processing
GLP-1 signaling appears to influence how amyloid precursor proteins are processed.
Researchers believe these medications may:
Reduce BACE activity
Decrease neurotoxic amyloid fragments
Reduce plaque accumulation
While the exact mechanisms remain under investigation, the preclinical evidence is increasingly compelling.
4. Improved Cerebral Blood Flow and Neuroprotection
GLP-1 medications may also support:
Vascular function
Mitochondrial health
Neuronal survival
Synaptic plasticity
These effects may extend beyond Alzheimer’s disease and influence overall cognitive performance throughout adulthood.
Why This Matters for ADHD
At first glance, ADHD and Alzheimer’s disease may seem completely unrelated.
In reality, they share several overlapping biological themes.
Many adults with ADHD struggle with:
Insulin resistance
Obesity
Sleep deprivation
Sedentary behavior
Chronic stress
Inflammation
These factors can negatively affect both executive functioning today and cognitive resilience decades later.
Research increasingly suggests that long-term brain health is not simply determined by genetics.
It is heavily influenced by metabolic health.
When I work with folks to during an ADHD evaluation in Washington DC, Maryland, New York, and beyond, we frequently discuss:
Nutrition
Metabolic biomarkers
Cardiovascular risk factors
Inflammation
These interventions are not just about improving symptoms today.
They may help preserve cognitive function for years to come.
The Integrative Psychiatry Perspective
One of the core principles of integrative psychiatry is that the brain does not exist in isolation.
The brain is connected to:
Metabolism
Hormones
Sleep
Exercise
Nutrition
Inflammation
Cardiovascular health
When we improve these systems, psychiatric symptoms often improve as well.
That does not mean every patient needs a GLP-1 medication.
Far from it.
However, this research reinforces the broader metabolic psychiatry framework:
Healthy metabolism supports healthy brain function.
Important Limitations
Despite the excitement surrounding these findings, several important caveats remain.
GLP-1 medications are not approved for Alzheimer’s prevention.
Human evidence remains limited.
Questions remain regarding:
Optimal dosing
Duration of treatment
Long-term safety
Effects in healthy individuals
Prevention versus treatment
Potential side effects also deserve consideration, including:
Nausea
Gastrointestinal symptoms
Loss of lean muscle mass with rapid weight loss
Cost and access concerns
More prevention-focused trials are urgently needed.
My Takeaway
The most important message from this review is not that everyone should start a GLP-1 medication.
The takeaway is that brain health and metabolic health are deeply interconnected.
The future of psychiatry is likely to involve a more comprehensive approach that integrates:
Mental health
Sleep
Exercise
Nutrition
Cardiovascular risk reduction
Cognitive preservation
GLP-1 receptor agonists may ultimately become one tool within that larger framework.
For now, the evidence is encouraging but preliminary.
If future human studies confirm what we are seeing in animal models, these medications could become part of a broader strategy aimed at preserving brain health long before Alzheimer’s disease develops.
That is a conversation worth paying attention to.
References
Corcoran E, Kettlety M, Mogul U, Azah JN, Cork SC. The Effects of GLP-1 Receptor Agonists on Alzheimer’s Pathophysiology: A Systematic Review. Molecular and Cellular Neuroscience. 2026.
Norwitz N. “Could GLP-1s Help Prevent Alzheimer’s?” Thread published June 11, 2026.
ELAD Trial Investigators.
EXSCEL Trial Investigators.
Additional observational dementia-risk analyses involving semaglutide and other GLP-1 receptor agonists.